Rayner
Christopher Willis has a comprehensive work experience in the healthcare industry. Christopher is currently the Vice President of Global Marketing at Rayner, where they lead the marketing, clinical, and digital health teams. Prior to this, they were the Head of Global Sales at Syneos Health Commercial Solutions, responsible for the commercial launch of a novel IOL globally.
Before joining Rayner, Christopher held the position of Sales Director, Northern Europe at Optos, where they successfully turned around the sales performance and achieved significant revenue growth. Christopher also launched important products during their tenure.
Christopher has also worked as a Global Commercial Director at AcuFocus, Inc., where they were responsible for global sales of various medical devices. Christopher achieved significant growth in sales and managed a diverse team across different regions.
Christopher's experience also includes working as a Global Marketing Director at Bausch & Lomb, handling the global cataract equipment business and launching several products. Christopher had earlier served as the European Marketing Manager at the same company.
In the early stages of their career, Christopher worked at 3M Health Care, where they held various roles including Senior Marketing Executive and Sales Representative, achieving exceptional sales results and launching new products.
Overall, Christopher Willis has demonstrated a strong track record of sales and marketing success in the healthcare industry, with a focus on medical devices and equipment.
Christopher Willis attended The Blue Coat CofE School from 1990 to 1997. Christopher obtained a BSc degree in Business Management from the University of Bradford, where they studied from 1997 to 2001. Additionally, they received a Certificate in Direct Marketing from CIM | The Chartered Institute of Marketing. However, the start and end years for their studies at CIM are unknown.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.